Siemens Healthineers (SHL) Status update summary

Financial performance and outlook

• Achieved 5.7% revenue growth in Q1, with strong margin expansion and EPS growth to €0.51.

• Free cash flow reached €810 million, more than tripling year-over-year.

• Book-to-bill ratio was 1.21, with expectations to normalize to around 1.1 for the full year.

• Q1 results were at the higher end due to strong transactional business in the U.S.

• Full-year guidance remains unchanged, with regional dynamics factored in.

Regional and segment dynamics

• U.S. faces tougher comparables in the second half, while China is expected to be flat after a weak Q1.

• Diagnostics segment growth is muted due to legacy business decline and volume-based procurement in China.

• Volume-based procurement in China impacts about 10% of diagnostics revenue, with effects expected through 2026.

• Market share in China for imaging is stable, with strength in higher-end segments.

• Guidance does not depend on a market rebound in China.

External risks and mitigation

• U.S. tariffs on imports from Mexico and other regions expected to have minor, manageable impacts.

• Foreign exchange tailwinds are expected to offset tariff headwinds for adjusted EPS in 2025.

• Healthcare sector considered lower risk in global trade wars due to its critical nature.

• Diversified global manufacturing footprint, with significant U.S. presence, reduces risk.